On October 12, ASBM Immediate Past Chair Madelaine Feldman, MD, FACR participated in a forum held by STAT, entitled “Biosimilars’ Meteoric Moment”. The forum focused on the long-awaited arrival of multiple adalimumab biosimilars in 2023 and asked experts from a variety of fields to speculate on what 2023 holds for the biosimilars market. Speakers included:

  • Madelaine A. Feldman, M.D., FACR, president, Coalition of State Rheumatology Organizations; clinical assistant professor of medicine, Tulane University School of Medicine
  • Steven Horvitz, president and founder, EMC Analytics Group
  • Darius Lakdawalla, Ph.D., director of research, USC Schaeffer Center for Health Policy & Economics; quintiles chair in pharmaceutical development and regulatory innovation, USC School of Pharmacy; professor, USC Price School of Public Policy
  • Michael Sherman, M.D., MBA, MS, executive vice president and chief medical officer, Point32Health
  • Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)
  • Thomas Newcomer, head of US market access, Samsung Bioepis (sponsor speaker)

During the one-hour panel discussion, Dr. Feldman discusses several factors which she believes will influence the success of the U.S. adalimumab biosimilar market, including interchangeability, recent federal legislation, and PBM formulary construction.

View video of the STAT Forum “Biosimilars’ Meteoric Moment” here.